Review of clinical applications of radiation-enhancing nanoparticles
N Scher1, S Bonvalot2, C Le Tourneau3,4,5
1Department of Radiation Oncology, Institut Curie, Paris, France.
Purpose:
Clinical evidence of the radiation-enhancing effects of nanoparticles has emerged.
Materials And Methods:
We searched the literature in English and French on PubMed up to October 2019. The search term was "nanoparticle" AND "radiotherapy", yielding 1270 results.
Results:
The two main NP used in clinical trials were hafnium oxide and gadolinium involving a total of 229 patients. Hafnium oxide NP were used in three phase 1/2 trials on sarcoma, head and neck squamous cell carcinoma or liver cancer and one phase 2/3 trial. There are six ongoing phase 1/2 clinical trials to evaluate the combination of gadolinium-based NP and RT for the treatment of brain metastases and cervical cancer.
Conclusion:
So far, intratumoral hafnium oxide nanoparticles were safe and improved efficacy in locally advanced sarcoma.
More Related Videos
07:59A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
10:51Protocols for Assessing Radiofrequency Interactions with Gold Nanoparticles and Biological Systems for Non-invasive Hyperthermia Cancer Therapy
Published on: August 28, 2013